Clinical Trial for Helathy.

This study has two parts: Part A and Part B.

The purpose of Part A of this study is to learn about the safety, tolerability, and how PF-07328948 is processed by the body when multiple doses of PF-07328948 are given to healthy participants.

The purpose of Part B of this study is to understand the amount of PF-07328948 that would be available in the body after taking a single pill. The amount will be compared to the amount of PF-07328948 in a suspension in healthy adults.

Part B will be conducted if the results of Part A support further study of PF-07328948.

The study is seeking participants who:

are females who are not able to give birth to a child of 18 years of age or older.
are males of 18 years of age or older.
have a BMI of 20.0 to 35.0 kg/m2.
have total body weight of more than 50 kg (110 lbs).

Participants in Part A will be randomly selected to receive either PF-07328948 or placebo (a pill that has no medicine in it).

Participants in Part B will receive PF-07328948 as suspension and tablet form, both taken by mouth after food or during fasting.

For a given participant in Part A , the total study is going to last up to about 12 weeks. This includes from the time of selection till the last follow-up phone call. The participants will be selected if they are fit for the study 28 days before the first dose of the study medicines. Participants who are selected will be admitted to the study site on Day -2 for around 19 days. Following discharge, participants will return for an on-site follow-up visit 7 to 10 days after receiving the final dose of the study medicine. The follow-up contact may be via a telephone call and will happen 28 to 35 days after the final dose of study medicine is given.

For a given participant in Part B, the total study is going to last up to about 10-12 weeks. This study consists of 3 periods. Participants will be admitted to the study site on Day -1 and discharged on Day 4 in each period. Participants may stay in the study site after completion of Day 4 activities as per the study head's decision. There will be a washout of approximately 7 days between dosing in each period.

Closest Location

To find study locations, use the location search box below.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Helathy

Sex

Male or Female

Age

18 - 60 years

View more eligibility criteria on ClinicalTrials.gov

Join PfizerLink — a clinical research registry

Join PfizerLink — a clinical research registry

A Study of Multiple Ascending Doses of PF-07328948 in Healthy Adult Participants

Who may participate